Clinical Trial Update: Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of MEDI-547 in relapsed or refractory solid tumors was terminated; the update provides information on safety, tolerability, and biologic activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MEDI-547

Snippet

Sponsor: MedImmune LLC | Conditions: Cancer | Phase 1 | Status: TERMINATED